Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer

Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treatment of dMMR/MSI-H metastatic CRC, combination the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasi, Pashtoon Murtaza, Budde, Griffin, Krainock, Michael, Aushev, Vasily N, Koyen Malashevich, Allyson, Malhotra, Meenakshi, Olshan, Perry, Billings, Paul R, Aleshin, Alexey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804692/
https://www.ncbi.nlm.nih.gov/pubmed/35101943
http://dx.doi.org/10.1136/jitc-2021-003312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804692/
https://www.ncbi.nlm.nih.gov/pubmed/35101943
http://dx.doi.org/10.1136/jitc-2021-003312

Ejemplares similares